THIS magazine’s comment that “drug companies must tell us all they know about the medicines we take” touched a raw nerve (1 May, p 3). It discussed unease about the effects of selective serotonin reuptake inhibitors (SSRIs) and reported that researchers working for the UK’s National Institute for Clinical Excellence (NICE), which advises on the safety and efficacy of treatments, had contacted drug companies about unpublished studies on SSRIs. Unforgivably, they were “met with a stony silence”.
I asked health minister Norman Warner whether his department shares the concerns about SSRIs and whether regulators should have more powers. He…
